APVO Stock — Aptevo Therapeutics Inc.: Cash, EV, Pipeline

Share price

$1.84

Market cap

$3.3M

Cash

$9.8M

Enterprise value

-$6.5M

Balance sheet

Cash	$9.8M
Debt	$0.0M
Net cash	$9.8M
Enterprise value	-$6.5M
Basic shares	1.4M shares
Fully diluted shares	9.0M shares
Fully diluted market cap	$16.5M
Cash per share	$7.00

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading APVO daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Nov 12 - Dec 24	APVO436	Phase 1	Acute Myeloid Leukemia (AML)	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Mipletamig

Phase 2 · Active Modality: bispecific antibody

Target CD123 x CD3

Indications

Acute myeloid leukemia (AML) (Phase 2)

Status note Lead clinical blood cancer candidate; bispecific ADAPTIR targeting CD123 x CD3. FDA orphan drug designation for AML (Nov 2019). Phase 1a monotherapy dose escalation and Phase 1b dose expansion completed; Phase 1b/2 RAINIER trial in frontline AML (combination with venetoclax + azacitidine) ongoing with dose optimization for RP2D selection.

ALG.APV-527

Phase 1 · Active Modality: bispecific antibody

Target 4-1BB (CD137) x 5T4

Partnerships Alligator Bioscience AB: collaboration and option agreement (July 20, 2017); 50/50 cost sharing; jointly owned collaboration IP with opt-out points

Indications

Solid tumors (Phase 1)

Status note Lead solid tumor candidate; bispecific ADAPTIR targeting 4-1BB (CD137) x 5T4. Phase 1 dose escalation trial completed; Aptevo and Alligator evaluating next steps for the dose expansion trial.

APVO603

Preclinical · Active Modality: bispecific antibody

Target 4-1BB (CD137) x OX40 (CD134)

Indications

Solid tumors (Preclinical)

Status note Preclinical bispecific ADAPTIR candidate targeting 4-1BB (CD137) x OX40 (CD134) (targets per 10-K fallback).

APVO711

Preclinical · Active Modality: bispecific antibody

Target PD-L1 x CD40

Indications

Cancer (Preclinical)

Status note Preclinical bispecific ADAPTIR candidate targeting PD-L1 x CD40 (targets per 10-K fallback).

Radiopharmaceutical oncology programs (Niowave collaboration)

Discovery · Active Modality: radiopharmaceutical

Partnerships Niowave: 50/50 collaboration agreement (May 25, 2026) to develop up to three radiopharmaceutical oncology programs combining Aptevo proprietary molecules with Niowave radioisotopes; supply agreement plus Niowave equity investment

Indications

Cancer (Discovery)

Status note Up to three radiopharmaceutical oncology programs; candidate names not disclosed in filing.

Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	APVO436
Lead indication	Acute Myeloid Leukemia (AML)
Lead phase	Phase 1
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06634394	Phase 1	Recruiting	Sponsor	Aptevo Therapeutics	—	Acute Myeloid Leukemia (AML)	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Aptevo Therapeutics on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

APVO — Aptevo Therapeutics Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials